Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report)’s share price traded up 20.1% during trading on Monday . The stock traded as high as $5.50 and last traded at $5.50. 1,750 shares were traded during trading, an increase of 46% from the average session volume of 1,202 shares. The stock had previously closed at $4.58.
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. HC Wainwright upgraded Idorsia from a “neutral” rating to a “buy” rating in a research note on Monday, September 15th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Idorsia in a research note on Friday, August 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.
Check Out Our Latest Analysis on Idorsia
Idorsia Stock Performance
Idorsia Company Profile
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.
Featured Stories
- Five stocks we like better than Idorsia
- How to Read Stock Charts for Beginners
- Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Exceptional Stocks to Build Long-Term Wealth
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Insider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
